Jeff Bird

Jeff Bird is a highly experienced professional in the fields of venture capital and healthcare. Currently serving as Managing Director at Bluebird Ventures since August 2019, Jeff Bird also holds the position of Limited Partner and Managing Director at Sutter Hill Ventures since June 2002. In addition, Jeff Bird is a Board Member at Stanford Health Care and actively invests in several companies, including Leyden Labs, Foresight Dx, Kriya Therapeutics, Nutcracker Therapeutics, Epirium, and Procyrion, Inc. Jeff Bird's educational background includes an MD and a Ph.D. in Cancer Biology from Stanford University School of Medicine, along with a Bachelor of Science degree from Stanford University.